Last reviewed · How we verify
DIPHENHYDRAMINE CITRATE
At a glance
| Generic name | DIPHENHYDRAMINE CITRATE |
|---|---|
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
Common side effects
Key clinical trials
- Trial of Diphenhydramine for Sleep in Children With Autism (PHASE2)
- Trial of Zolpidem for Sleep in Children With Autism (PHASE2)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
- Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (PHASE2)
- Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) (PHASE1)
- IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patient's Quality Of Life (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |